Mission Pharmacal Company Mission Pharmacal, maker of the “Orphan Drugs” Thiola™ (Tiopronin) and Urocit®-K, (Potassium Citrate) states a strong commitment to the research and development of therapeutics and diagnostic procedures
LithoLink Corporation Headed by Fredric Coe, MD, and John Asplin, MD, Litholink is focused on the prevention of kidney stone formation. Litholink’s programs and testing can be utilized by local
Cystinuria Clearinghouse
Cystinuric Perspectives
“Ureteroscopy” by Michael Grasso, M.D. An eMedicine article (WebMD) written by Dr. Michael Grasso (Chairman, Department of Urology, Saint Vincent’s Medical Center, Manhattan; Professor and Vice Chairman, Department of Urology,
“Percutaneous Endourology” by Michael Grasso, M.D. An eMedicine article (WebMD) written by Dr. Michael Grasso (Chairman, Department of Urology, Saint Vincent’s Medical Center, Manhattan; Professor and Vice Chairman, Department of
“Extracorporeal Shockwave Lithotripsy” by Michael Grasso, M.D. An eMedicine article (WebMD) written by Dr. Michael Grasso (Chairman, Department of Urology, Saint Vincent’s Medical Center, Manhattan; Professor and Vice Chairman, Department
“Intracorporeal Lithotripsy” by Michael Grasso, M.D. An eMedicine article (WebMD) written by Dr. Michael Grasso (Chairman, Department of Urology, Saint Vincent’s Medical Center, Manhattan; Professor and Vice Chairman, Department of
International Kidney Stone Institute (IKSI) This not-for-profit organization headed by James Lingeman, M.D., and Andrew Evan, Ph.D., focuses on kidney stone prevention and treatment research. The IKSI web site contains
Rare Kidney Stone Consortium The Consortium facilitates cooperative exchange of information and resources among investigators, clinicians, and patients, and researchers in order to improve care and outcomes for patients with